LONZA GROUP ADR EBIT

The latest EBIT for LZAGY is $2.6B as of June 2026. That compares with $2.8B in the prior-year period — down 5.2% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside LONZA GROUP ADR's historical trend and sector peers before judging valuation or financial health.

Over the past year, LZAGY's EBIT moved from $2.8B to $2.6B — a 5.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LONZA GROUP ADR's operating scale or balance-sheet position.

Against Healthcare companies, LZAGY currently prints $2.6B for EBIT, while the sector average sits near $110B. That is roughly 97.5% below the sector mean. Large gaps often invite a closer look at LONZA GROUP ADR's growth, margins, and balance sheet.

A EBIT figure of $2.6B for LZAGY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting LZAGY's EBIT ($2.6B), review year-over-year change from $2.8B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.